Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

2014 ASH Annual Meeting

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma,” presented by Matthew A. Lunning, DO.

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Related Videos

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

BPDCN FDA Approves Pivekimab Sunirine-pvzy

After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention

Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

Early Breast Cancer Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy